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Abstract
A 58 year old lady presented with a right breast cancer and a prior history of malignant melanoma
excised from the right chest wall eight years previously. An abnormal axillary lymph node resected
contained features of both metastatic breast carcinoma and malignant melanoma. Following
oncologic breast cancer management, the patient is well with no evidence of recurrence at three
years.
Background
There is an increased incidence of breast cancer as a sec-
ond primary tumour in women previously diagnosed
with a malignant melanoma [1]. Any direct association is
at best controversial [2] and common aetiogical factors
remain elusive. One plausible link may be hormonal in
origin as oestrogen receptors are expressed in up to half of
malignant melanomas [3] and at least two-thirds of breast
cancers.
There are isolated case reports of melanoma and carci-
noma found together in the primary tumour mass in
breast [4], lung [5], oral cavity [6,7]. Cancer-to-cancer
metastasis with evidence of melanoma metastases to pri-
mary renal cell carcinoma [8] is also documented. There is
only one report of synchronous involvement in the meta-
static axillary lymph node retaining the dual histology of
the breast tumour exhibiting melanoma and carcinoma
components [4]. We report on a lymph node containing
two different primary cancer types that may result in dis-
tinct clinical management and have different prognostic
implications for the patient.
Case report
A 58 year old lady presented with a 2.5 cm right breast
lump inferior to the nipple with skin tethering and a pal-
pable malignant right axillary lymph node. She had exci-
sion of a right chest wall malignant melanoma Clark's
level IV (1.18 mm maximum thickness) eight years prior.
There were no palpable axillary nodes at that time. Mam-
mogram, ultrasound and fine needle aspiration cytology
of the breast lump confirmed breast cancer. Core biopsy
of the right axillary lymph node showed high grade malig-
nancy including pigmented cells, possibly originating
from the malignant melanoma. She underwent right wide
local excision and axillary nodal clearance. Histopathol-
ogy revealed a 19 mm, grade 3 infiltrating ductal carci-
noma of the breast of medullary phenotype with no
lymphovascular invasion that was ER, PgR and HER-2
negative. Breast tumour cells in the primary cancer were
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positive for CAM 5.2, AE1, AE3 and EMA and negative for
S100 and HMB45. Right axillary nodal clearance showed
one out of nine lymph nodes contained metastatic cancer
with a large area of necrosis and 2 distinct tumour types
(Figure 1). One morphological type was of epithelial ori-
gin with cells arranged in cohesive sheets. These areas
were positive for CAM 5.2, AE1, AE3 and EMA (Figure 2).
Other areas were highly pleomorphic containing cells
with prominent nucleoli arranged in loose dissociate clus-
ters that were strongly positive for S100 protein and
focally for HMB45; negative for EMA and CAM 5.2 (Figure
3). The lymph node metastases therefore contained fea-
tures of metastatic breast carcinoma and malignant
melanoma in the same metastatic focus. Staging CT of her
thorax, abdomen and pelvis as well as a bone scan were
negative for distant spread. The patient was treated with
adjuvant chemotherapy for breast cancer with 5 fluorour-
acil, epirubicin and cyclophosphamide for six cycles fol-
lowed by radiotherapy to the breast. She remains well
with no evidence of breast cancer or melanoma recurrence
three years later.
Discussion
Early diagnosis and better treatment protocols have led to
significant improvements in disease free and overall sur-
vival following a diagnosis of cancer. It is therefore
becoming increasingly common for patients to be diag-
nosed with a second primary tumour in their lifetime, par-
ticularly in patients with primary malignant melanoma
[1,2]. The possible explanations include familial factors,
the increasing natural lifespan of patients, and improved
outcome following previous cancer treatment.
The primary breast cancer in our case did not contain
melanoma cells that might have arisen through collision
between two histologically different primary tumours,
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nor was there any pathological evidence of metaplasia,
neuroendocrine differentiation or cancer to cancer metas-
tases. The presence of two metastatic cell phenotypes in
the axillary lymph node with different immunohisto-
chemistry profiles is likely to have occurred in a meta-
chronous fashion with the melanoma metastasis being
detected incidentally during axillary dissection for breast
carcinoma. The involved lymph node in probability rep-
resented the true sentinel node draining the skin of the
chest wall and the breast. It is possible that melanoma
micrometastases was dormant in the axillary lymph node
and did not progress to clinical significance following the
melanoma diagnosis. Melanoma micrometastases may
therefore not be prognostically equivalent to overt nodal
metastases and may reflect the natural history of
melanoma micrometastases in the sentinel lymph node
[9]. Barnhill et al [10] demonstrated that melanoma
micrometastases lack significant rates of proliferation,
apoptosis and neo-vascularisation when compared with
macrometastases as the angiogenic and lymphangiogenic
factors may be suppressed by host immune responses.
Subsequent management and follow-up of patients such
as ours depend on the competing risks and natural history
of the two separate primary cancers. In this case, adjuvant
breast cancer treatment was of priority with continued
surveillance of the melanoma.
The common sentinel node draining the breast and the
trunk skin probably reflects the dominant lymphatic pat-
tern of ectodermal structures and adds to the anatomical
evidence to support the concept of the first draining node
to a regional basin. The application of new technologies
to cancer staging has to be guided by the natural history of
the various cancer types. Detection of regional metastases
has different prognostic implications for breast cancer and
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melanoma and management decisions need to be made
on evidence based clinical criteria rather than any inciden-
tal findings.
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